Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
151 hedge funds and large institutions have $1.02B invested in Cymabay Therapeutics in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 32 closing their positions.
1,611% more call options, than puts
Call options by funds: $3.85M | Put options by funds: $225K
41% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 32
31% more capital invested
Capital invested by funds: $775M → $1.02B (+$242M)
9% more funds holding
Funds holding: 139 → 151 (+12)
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$45.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$23.5M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$18.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15.3M |
| 5 |
Jennison Associates
New York
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$26.6M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$15.9M |
| 3 |
Millennium Management
New York
|
-$14M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$11.5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.92M |
CBAY Hedge Fund Activity: Q2 2023 in Review
151 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2023, worth a combined $1.02B — up 31% from $775M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CBAY positions and 32 closed out — a net gain of 13 holders — while 42 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $45.2M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $26.6M sold.
- 151 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2023, up from 139 in Q1 2023.
- Funds reported $1.02B of Cymabay Therapeutics stock for Q2 2023, up 31% quarter-over-quarter.
- 45 funds opened new Cymabay Therapeutics positions in Q2 2023 and 32 closed out, a net change of +13 holders.
- The largest Cymabay Therapeutics buyer in Q2 2023 was BlackRock, an estimated $45.2M added.
- The largest Cymabay Therapeutics seller in Q2 2023 was TCG Crossover Management, an estimated $26.6M sold.
Based on aggregated 13F filings for Q2 2023.